InflammoPharmacology

, Volume 12, Issue 5–6, pp 591–596 | Cite as

The kallikrein-kinin system: from mediator of inflammation to modulator of cardioprotection

  • Jagdish N. Sharma
Article

Abstract

Kinin is an important mediator of hyperalgesia, inflammatory conditions and asthma. It causes pain, inflammation, increased vascular permeability and vasodilatation. Several kinin antagonists have been developed with the aim of treating these pathologies. Kinin B2 receptor agonists and kallikrein may have clinical utility in the treatment of hypertension, left ventricular hypertrophy, ischemic heart disease, congestive heart failure and diabetes. However, there is a need to know whether there is a safe therapeutic window between potential cardio-protective and pro-inflammatory effects following administration of kinin B2 receptor agonists.

Key words

Kinin kallikrein inflammatory reactions kinin receptor antagonist kinin receptor agonist hypertension left ventricular hypertrophy diabetes 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chao, J. and Chao, L. (1998). Kallikrein gene therapy in hypertension, cardiovascular and renal diseases, Gen. Ther. Mol. Biol. 1, 301–308.Google Scholar
  2. Bathon, J. M., Manning, D. C., Goldman, D. W., et al. (1992). Characterization of kinin receptors on human synovial cells and upregulation of receptor numbers by interleukin-1, J. Pharmacol. Exp. Ther. 260, 384–392.PubMedGoogle Scholar
  3. Burch, R. M. and DeHaas, C. (1990). A bradykinin antagonist inhibits carrageenan edema in rats, Naunyn-Schmiedeberg’s Arch. Pharmacol. 342, 189–193.CrossRefGoogle Scholar
  4. Di Rosa, M., Giroud, J. P. and Willoughby, D. A. (1971). Studies of the mediators of acute inflammatory response induced in rats in different sites by carrageenana and turpentine, J. Pathol. 104, 15–29.PubMedCrossRefGoogle Scholar
  5. Kichuck, M. R., Seyedi, N., Zhang, X., et al. (1996). Regulation of nitric oxide production in human coronary microvessels and the contribution of local kinin formation, Circulation 94, 44–51.Google Scholar
  6. Koide, A., Zeitlin, I. J. and Parratt, J. R. (1993). Kinin formation in ischemic heart and aorta of anaesthetized rats, J. Physiol. 467, 125P.Google Scholar
  7. Linz, W., Wiemer, G. and Scholkens, B. A. (1993). Bradykinin prevents left ventricular hypertrophy in rats, J. Hypertens. 11(Suppl. 5), S96–S97.Google Scholar
  8. Ljunggren, O. and Lerner, U. H. (1990). Evidence for Bk1 bradykinin receptor-mediated prostaglandin formation in osteoblasts and subsequent enhancement of bone resorption, Br. J. Pharmacol. 101, 382–386.PubMedGoogle Scholar
  9. Locherner, W. and Parratt, J. R. (1966). A comparison of the effects of locally and systematically administration of kinin on coronary blood flow and myocardial metabolism, Br. J. Pharmacol. Chemother. 26, 17–26.Google Scholar
  10. Morgolius, H. S., Geller, A., de Jong, W., et al. (1972). Altered urinary kallikrein excretion in rats hypertension, Circ. Res. 30, 358–362.Google Scholar
  11. Sharma, J. N. (1991). The role of kallikrein-kinin system in joint inflammatory disease, Eur. J. Rheumatol. Inflamm. 11, 30–36.PubMedGoogle Scholar
  12. Sharma, J. N. (2003). Does the kininn system mediate in cardiovascular abnormalities? An overview, J. Clin. Pharmacol. 43, 1187–1195.PubMedCrossRefGoogle Scholar
  13. Sharma, J. N. and Buchanan, W. W. (1994). Pathogenic responses of bradykinin system in chronic inflammatory rheumatoid disease, Exp. Toxicol. Pathol. 46, 421–433.PubMedGoogle Scholar
  14. Sharma, J. N. and Wirth, K. J. (1996). Inhibition of rats adjuvant arthritis by a bradykinin antagonist Hoe 140 and its influence on kallikrein, Gen. Pharmacol. 27, 133–136.PubMedCrossRefGoogle Scholar
  15. Sharma, J. N., Amrah, S. S. and Noor, A. R. (1995). Suppression of hypotensive responses of captopril and enalapril by kallikrein inhibitor aprotinin in spontaneously hypertensive rats, Pharmacology 50, 363–369.PubMedCrossRefGoogle Scholar
  16. Sharma, J. N., Yusof, A. P. M. and Wirth, K. J. (1998). The kinin antagonist Hoe 140 reduces acute paw oedema in rats caused by carrageenan, bradykinin and kaolin, Inflammopharmacology 6, 9–17.PubMedGoogle Scholar
  17. Sharma, J. N., Zubaid, M., Khan, B. Z. S. J., et al. (2000). Pathphysiological activities of the kallikrein-kinin system with emphasis on the cardiovascular disorders, Inflammopharmacology 8, 219–241.CrossRefGoogle Scholar
  18. Sharma, J. N. and Sharma, J. (2002). Cardiovascular properties of the kallikrein-kinin system, Curr. Med. Res. Opin. 18, 10–17.PubMedCrossRefGoogle Scholar
  19. Sharma, J. N., Uma, K. and Yusof, A. P. M. (1998). Left ventricular hypertrophy and its relation to cardiac kinin-forming system in hypertensive and diabetic rats, Int. J. Cardiol. 63, 229–235.PubMedCrossRefGoogle Scholar
  20. Sharma, J. N., Abbas, S. A., Yusof, A. P. M., et al. (2003). Evaluation of tissue kallikrein activity on survival time after acute coronary artery ligation in hypertensive rats, Int. Immunopharmacol. 3, 329–334.PubMedCrossRefGoogle Scholar
  21. Sharma, J. N., Abbas, S. A., Yusof, A. P. M., et al. (2004). Tissue kallikrein increases survival after prolonged coronary artery ligation in hypertensive rats, Pharmacology 70, 201–205.PubMedCrossRefGoogle Scholar
  22. Zhu, P., Zugga, C. E., Simper, D., et al. (1995). Bradykinin improves post-ischaemic recovery in that rat heart: role of high energy phosphate, nitric oxide and prostacyclin, Cardiovasc. Res. 29, 658–663.PubMedCrossRefGoogle Scholar

Copyright information

© VSP 2005

Authors and Affiliations

  • Jagdish N. Sharma
    • 1
  1. 1.Department of Applied Therapeutics, Faculty of Pharmacy, Health Sciences CentreKuwait UniversitySafatKuwait

Personalised recommendations